Incidence trends of aplastic anaemia in Kazakhstan: a nationwide study (2014–2024)
-
By
-
Zhanna Sarbassova
-
Ulday Akhmetova
-
Balnur Iskakova
-
Nargiz Nassyrova
-
Lyazzat Kosherbayeva
-
Nurgul Alekenova
-
June 22, 2026
-
Clinical Scorecard: Trends in the Incidence of Aplastic Anaemia Across Kazakhstan: A Nationwide Analysis from 2014 to 2024
At a Glance
| Category | Detail |
|---|
| Condition | Aplastic Anaemia |
| Key Mechanisms | Failure of bone marrow to produce adequate blood cells, often due to immune-mediated destruction of hematopoietic stem cells. |
| Target Population | General population of Kazakhstan, with a median age of 26 years. |
| Care Setting | Population-based epidemiological study. |
Key Highlights
- 1,209 incident cases of aplastic anaemia identified from 2014 to 2024.
- National incidence increased from 0.21 to 0.82 per 100,000 population.
- 88.9% of cases classified as idiopathic or unspecified.
- Highest incidence observed in major urban centers, reaching 1.48 per 100,000 in 2024.
- Geographic disparities suggest differences in healthcare access.
Guideline-Based Recommendations
Diagnosis
- Utilize ICD-10 code D61 for identification of aplastic anaemia cases.
Management
- Consider immunosuppressive therapy and allogeneic hematopoietic stem cell transplantation for treatment.
Monitoring & Follow-up
- Strengthen surveillance systems for better detection and management of aplastic anaemia.
Risks
- Untreated aplastic anaemia is associated with high mortality.
Patient & Prescribing Data
Patients diagnosed with aplastic anaemia in Kazakhstan.
Immunosuppressive therapy has improved prognosis and survival outcomes.
Clinical Best Practices
- Focus on regional genetic profiling to understand susceptibility.
- Address healthcare access disparities to improve diagnosis and treatment.
Related Resources & Content
